Takeda S, Uchida J, Yamada Y, Unemi N, Fujii S
Osaka Foundation for Promotion of Fundamental Medical Research.
Gan To Kagaku Ryoho. 1988 Jul;15(7):2125-30.
We investigated the relationships between antitumor activity and the inhibition of Thymidylate Synthase (TS) activity after oral administration of 5-fluorouracil (FUra) and its derivatives, FT, UFT, HC-FU, PH-FU and 5'-DFUR, using mainly Sarcoma 180 as an experimental tumor model. The inhibition of TS activity in the tumor, after oral administration of these drugs to Sarcoma 180 bearing mice, reached the plateau phase shortly after drug administration. The inhibition of TS activity remained at the same level for over 24 hours and was dose dependent. UFT and FT showed a very high correlation between the inhibition of TS activity and their antitumor activity. However, such a correlation was not found for other FUra derivatives despite their high TS inhibiting values. The relationship between the tumor growth inhibition (TGI) and the TS inhibition (TSI) of these drugs, presented as a ratio of ED50 of TGI to ED50 of TSI in case of UFT and FT, was shown to be 0.81 and 1.18, respectively (i.e., nearly 1.00). However, the above ratio for FUra and HCFU was shown to be 2.49 and 3.88, respectively. These findings demonstrate that it is necessary to take into account other mechanisms besides TS inhibition of some fluorinated pyrimidines to explain their total antitumor activity.
我们以肉瘤180作为实验肿瘤模型,研究了口服5-氟尿嘧啶(FUra)及其衍生物FT、UFT、HC-FU、PH-FU和5'-DFUR后,其抗肿瘤活性与胸苷酸合成酶(TS)活性抑制之间的关系。给荷肉瘤180小鼠口服这些药物后,肿瘤中TS活性的抑制在给药后不久即达到平台期。TS活性的抑制在24小时以上保持在同一水平,且呈剂量依赖性。UFT和FT在TS活性抑制与其抗肿瘤活性之间显示出非常高的相关性。然而,尽管其他FUra衍生物具有较高的TS抑制值,但未发现这种相关性。这些药物的肿瘤生长抑制(TGI)与TS抑制(TSI)之间的关系,以UFT和FT为例,表现为TGI的ED50与TSI的ED50之比,分别为0.81和1.18(即接近1.00)。然而,FUra和HCFU的上述比值分别为2.49和3.88。这些发现表明,除了TS抑制外,还必须考虑一些氟嘧啶的其他机制来解释它们的总抗肿瘤活性。